A New Approach to MEK Inhibition for First-Line Treatment

For a cancer drug to help patients, it has to be a drug they can actually keep taking.

That may sound obvious, but it has been a longstanding challenge for drugs that block MEK, a key part of a growth-signaling pathway that is frequently switched on in pancreatic cancer. Earlier MEK inhibitors have shown some anticancer activity, but side effects and the cancer’s ability to route around the blocked pathway have limited their usefulness.

A new phase III trial is testing whether a next-generation MEK inhibitor called atebimetinib can overcome both problems and, when paired with a less intensive chemotherapy schedule, help people with metastatic pancreatic cancer live longer without sacrificing quality of life.

“If people can’t tolerate the drug, no matter how effective it is, that right there is a pause point,” says Eileen O’Reilly, M.D., a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York and a principal investigator of the trial.

The MAPKeeper 301 trial is testing atebimetinib in combination with chemotherapy as a first treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). The study plans to enroll approximately 510 participants and compare the combination with standard gemcitabine and nab-paclitaxel chemotherapy. Early results have provided reason for optimism, and the new randomized study will determine whether those findings hold up in a much larger group of patients.

Going After MEK

To understand the thinking behind atebimetinib, it helps to start with RAS.

RAS acts like a growth switch inside cells. Mutations that leave that switch turned on are extremely common in pancreatic ductal adenocarcinoma. MEK sits farther down that same signaling pathway, making it another potential place to interrupt the cancer-growth signal.

Scientists have been trying to exploit that vulnerability for years. The problem is that previous MEK inhibitors have run into two major obstacles: toxicity and resistance. Continuous pathway suppression also affects healthy cells, leading to problems such as diarrhea, nausea, rash, and retinal toxicity. And cancer cells have found ways to activate alternate signaling routes and essentially bypass the blockade.

Atebimetinib, an investigational oral MEK inhibitor developed by pharmaceutical company Immuneering, takes a different approach. It is designed to hit the pathway hard, then back off.

Although patients take a pill every day, blood levels of the drug rise sharply and then fall quickly. The approach is called deep cyclic inhibition, and the idea behind it is to give cancer cells a powerful daily hit while providing healthy cells time to recover. It is also intended to make it harder for cancer cells to activate some of the bypass pathways that have limited previous MEK inhibitors. “You get a big surge of the drug against the malignant cells, but you also mitigate some of the toxicity that’s been very problematic,” O’Reilly explains.

Preclinical studies of pancreatic cancer models found that atebimetinib had anticancer activity on its own and that combining it with chemotherapy produced greater suppression of cancer-cell growth, she adds.

Creators and clinicians wondered: Can we use less chemotherapy while adding a targeted therapy, and end up with a treatment that works better and is easier to sustain?

Adding Targeted Therapy While Dialing Back Chemotherapy

The MAPKeeper 301 trial is doing two things at once: adding atebimetinib and modifying the chemotherapy schedule. The study will also answer whether the experimental approach can outperform conventional gemcitabine/nab-paclitaxel.

Gemcitabine plus nab-paclitaxel, often shortened to GnP, is one of several chemotherapy combinations used to treat metastatic pancreatic cancer. Other first-line regimens include modified FOLFIRINOX and NALIRIFOX. O’Reilly says GnP was chosen for this trial because it can be used in a broader patient population and lends itself particularly well to combination with another therapy.

On the standard schedule used in the control arm of MAPKeeper 301, patients receive GnP chemotherapy on days 1, 8, and 15 of a 28-day treatment cycle. Patients assigned to the experimental arm instead receive chemotherapy on days 1 and 15 along with atebimetinib taken daily.

“I think this every-other-week schedule is a very attractive element of the experimental arm of the MAPKeeper 301 trial,” O’Reilly notes. “Patients like it, physicians like it, and as long as it preserves efficacy, I think it is an attractive way to de-escalate chemotherapy and integrate targeted medications.”

Why Researchers Are Paying Attention

Interest in the phase III study follows encouraging findings from an earlier phase IIa study of atebimetinib plus modified gemcitabine/nab-paclitaxel.

Among 55 previously untreated patients with metastatic pancreatic cancer, median overall survival was 17.3 months. Median progression-free survival (the length of time before the cancer grew or spread) was 8.3 months. Thirty-six percent of patients had a confirmed tumor response, while 82 percent achieved disease control.

Historically, median overall survival with gemcitabine/nab-paclitaxel has been considerably shorter, making the 17.3 month results particularly striking.

It is worth noting that the phase II study was a single arm trial, meaning everyone received atebimetinib plus chemotherapy. There was no randomized control group, so researchers cannot know whether the addition of atebimetinib was responsible for the longer-than-expected survival, or whether patient selection, subsequent treatments or other factors contributed. The MAPKeeper 301 trial is designed to resolve that question.

Living Better as Well as Longer

Overall survival is the primary endpoint of MAPKeeper 301, with progression-free survival, response, disease control, safety, and quality of life among the other outcomes being measured.

Quality of life may be particularly important in pancreatic cancer, where both the disease and its treatment can take a substantial physical toll. The earlier atebimetinib study offered some potentially encouraging hints. Among patients with available data, 84 percent maintained or gained weight at three months—an interesting finding in a disease where weight loss and cachexia are common.

Whether the treatment actually improves or preserves quality of life will be tested prospectively in the randomized trial. Researchers will use established questionnaires to follow patients’ quality of life over time and look at how long it takes before a clinically meaningful deterioration occurs.

For O’Reilly, these measurements are more than an optional extra. “If something is truly working and more efficacious, quality of life should be better for longer,” she says.

Part of a Rapidly Changing Treatment Landscape

For someone who has spent years developing treatments for pancreatic cancer, O’Reilly says the number of potentially practice-changing phase III studies now underway in newly diagnosed metastatic disease is exciting. “The state of play of pancreas cancer in 2026 is thankfully significantly more complicated than it was two years ago,” she adds.

The hope isn’t necessarily that one treatment emerges as the answer for everybody. Instead, several successful trials could eventually give patients and oncologists choices based on the molecular characteristics of a tumor, a patient’s overall health, and the patient’s own priorities.

“Hopefully a good number of these are going to meet the primary endpoints and we’ll have not one or two, but multiple choices in the front line,” O’Reilly states. “Choices are good for patients.”